Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study.

Edouard L FuMarie EvansCatherine M ClaseLaurie A TomlinsonMerel van DiepenFriedo W DekkerJuan J Carrero

Published in: Journal of the American Society of Nephrology : JASN (2020)

In this nationwide observational study of people with advanced CKD, stopping RAS inhibition was associated with higher absolute risks of mortality and major adverse cardiovascular events, but also with a lower absolute risk of initiating KRT.

Keyphrases

cardiovascular events
chronic kidney disease
coronary artery disease
cardiovascular disease
human health
wild type
cross sectional
risk assessment
adverse drug
climate change
drug induced